| Date | Title | Description |
| 27.08.2024 | JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma | SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Med... |
| 31.05.2024 | FDA Roundup: May 31, 2024 | SILVER SPRING, Md., May 31, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:
Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the ... |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID19 Pandemic Top Players Industry Trends and Forecast 2032 | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭. This comprehen... |
| 08.04.2019 | Startup of the Year nominees share tips for success — cast your vote now for the GeekWire Awards | Seattle startup Crowd Cow accepts the Startup of the Year award at the 2018 GeekWire Awards. (GeekWire Photo / Kevin Lisota)
A quick gander at the GeekWire 200, our index of Pacific Northwest startups, shows the density of up-and-coming tec... |
| 01.02.2018 | Is too much money being invested in oncology? | Oncology is to funding as gravity is to everything else – but is it over the top? Is cancer investment too much, too little or just right?
“I’ve been asking this for a number of years,” said Jay Lichter, managing director at Avalon Ventures... |
| 17.01.2018 | Term Sheet — Wednesday, January 17 | 5 Qs WITH A DEALMAKER
Krishna Yeshwant is not your typical VC. In addition to practicing internal medicine, Yeshwant is a general partner at GV (formerly Google Ventures), where he heads the Life Sciences team. His portfolio includes compan... |
| 04.01.2018 | Bristol-Myers Squibb Leads $75M Series B For Personal Genome Diagnostics | Personal Genome Diagnostics Inc. (PGDx) today announced a $75 million Series B financing co-led by new investor Bristol-Myers Squibb and existing investor New Enterprise Associates (NEA). Other new and existing investors including Inova Str... |
| 06.12.2017 | Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA | Juno Therapeutics $JUNO is adding a new approach to its BCMA strategy for multiple myeloma after forging an in-licensing deal through a trio of alliances that includes Eli Lilly.
Lilly is handing over rights on LY3039478 ... |
| 03.03.2017 | Seattle Week in Review: Healing Music Echoes Over ‘Voice City’ | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
It’s still winter, and March, as the saying goes, is coming in like a lion—or a juvenile bald eagle—with snow in the forecast for the weekend. Again. We’re wrapping the week w... |
| 05.12.2016 | Juno gets some badly needed relief after a glimpse of upbeat early data on JCAR017 | Anxious to turn the page on a deadly series of cerebral edema cases, Juno Therapeutics today turned to an upbeat set of preliminary data for JCAR017, which may soon emerge as its top drug in the pipeline.
Twelve of 20 patien... |
| 30.11.2016 | Bluebird bio announces positive CAR-T results | Just over four months ago, the FDA put a temporary hold on the same Phase 2 ROCKET trial after two patients died of cerebral edema, the same cause of death in last week’s announcement. The FDA gave the all-clear five days later and allowed ... |
| 24.11.2016 | Latest deaths in Juno trial underscore the need for greater transparency in clinical trials | The deaths last spring of three patients in a clinical trial of an experimental cancer treatment made by Juno Therapeutics was tragic news and cause for reflection on FDA oversight of investigational new drugs. The company’s announcement We... |
| 04.10.2016 | Juno CEO: Washington state biotech is ‘going backwards,’ needs support from Olympia to catch up | Juno Therapeutics CEO Hans Bishop speaking at the 2016 GeekWire Summit. Photo by Dan DeLong for GeekWire
While Washington state’s biotech industry is on the up and up, it still lags far behind hubs like San Francisco and Cambridge, Mass.
Wa... |
| 11.09.2016 | AI is for real and intelligent apps is its vehicle according to Madrona Group’s Matt McIlwain | Jasper Kuria Contributor
Jasper Kuria is the founder and editor of Capital & Growth.
More posts by this contributor
Pioneer Square Labs’ Greg Gottesman on the studio model for high growth startups
Gil Penchina on angel investing, market... |
| 08.09.2016 | Stung by patient deaths, a small Juno study points to a Goldilocks formula for CAR-T | For Juno, the hunt to find just the right mixture of T cells along with an effective regimen to prep patients for their CAR-T therapy has had a lethal history, tangling up development timelines in a way that has ceded the le... |
| 16.08.2016 | Juno Therapeutics sued on securities fraud allegations following patient death | Hans Bishop, Juno Therapeutics CEO, was named as a defendant in the lawsuit.
Juno Therapeutics, a Seattle-based clinical cancer research firm valued at $3.8 billion, has been sued in a class-action lawsuit alleging that the company violated... |
| 04.08.2016 | Juno posts loss as it amps up R&D spending for cancer trials | Photo via Juno.
It’s been a busy quarter for Juno Therapeutics with several different immunotherapy trials underway and a big hiring push as it expands research capabilities.
The Seattle-based biotech giant, which re-engineers the immune sy... |
| 04.08.2016 | Deaths derail Juno's launch countdown, giving Kite and Novartis the lead | The FDA’s hold on Juno Therapeutics’ lead CAR-T program, JCAR015, lasted only six days. But the derailment was serious enough to push its expected approval date from 2017 back into 2018, leaving Kite Pharma and Novartis an... |
| 14.07.2016 | And then there were 4: Juno adds another victim in CAR-T death tally | Juno’s CAR-T drugs didn’t just kill three people in clinical trials. They actually killed 4, as the company notes in its “revised” remarks from last week’s transcript of a call with company analysts. And the followup raise... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 18.06.2016 | Revealed: EY names 2016 Entrepreneur of the Year winners for Pacific NW | Master of ceremonies Jenni Hogan, left, and EY’s Greg Beams, far right, with EY regional Entrepreneur of the Year Award winners Scott and Ally Svenson of Mod Pizza; Sam Blackman of Elemental Technologies; Luke Kanies of Puppet; Matt Oppenhe... |
| 22.01.2016 | CRISPR gene editing: A commercial timeline | January 2015
Novartis signs two deals with Intellia Therapeutics and Caribou Biosciences to engineer immune cells and blood stem cells, meant for drug discovery research.
AstraZeneca signs four deals with the Wellcome Trust Sanger Institute... |
| 05.01.2016 | These infographics outline Editas’ post-IPO strategy | Here’s an interesting infographic from the prospectus that outlines Editas’ plans for expansion, in a three-step plan. Each figure accounts for 5,000 patients with inherited diseases that could benefit from a therapy that corrects the disea... |
| 06.12.2015 | Sovereign wealth fund investment in healthcare is on the rise, especially in digital health | “Healthcare is a necessity for people and for the United States, the sector represents a significant proportion of GDP, Maduell said. “With regards to the United States, it remains a deep liquid market compared to other countries.”
Sovereig... |
| 24.03.2015 | 30 Startups with the Biggest Funding Rounds in 2014 | In the 2014 fiscal year, $50 billion in venture funding was invested in 5,900 companies – an average of $8.5 million per deal. Mattermark's annual report on startup activity recently ranked the biggest funding rounds from 2014, and many sta... |
| 06.08.2014 | Juno Therapeutics Closes $134M Series B Financing | Juno Therapeutics, Inc., a Seattle, WA-based biotechnology company focused on advancing novel immunotherapies for cancer, closed a $134m Series B financing.
This round included new investments by ten public mutual funds and healthcare-focus... |
| 05.08.2014 | Juno Therapeutics Inks $134M Series B Round |
SEATTLE, WA, Biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced that it has closed its Series B round with $134M in new investment.
>> Click here for more funding data on Juno Therap... |
| 05.08.2014 | New Series B brings cancer immunotherapy startup Juno Therapeutics to $310 million just this year | “What I can tell you,” CEO Hans Bishop said in a phone interview, “is that the funds invested in this round are some of the highest quality healthcare investors in the country.”
When funding comes from large public funds, or “super-investor... |
| 25.04.2014 | Juno Therapeutics Closes $176M Series A Funding | Juno Therapeutics, a Seattle, WA-based biotech company focused on developing immunotherapies for cancer, has raised an additional $31m in Series A funding, closing the round at $176m.
Juno’s initial funding of $120m came from ARCH Venture P... |
| 24.04.2014 | Jeff Bezos-backed Juno Therapeutics closes series A at $176M, appoints new execs | Seattle biotechnology startup Juno Therapeutics, which is developing immunotherapies for cancer, said it has closed its series A financing round at $176 million.
That marks one of the largest early-stage financing rounds for a biotechnology... |
| 14.01.2014 | Juno Therapeutics Raises $25M in Funding | Juno Therapeutics, a Seattle, WA-based developer of immunotherapies for cancer, raised $25m in funding.
Backers included Bezos Expeditions and Venrock.
The company, which has now raised more than $145m, intends to use the funds to accelerat... |
| 14.01.2014 | Juno Therapeutics Inks Mega $120M Series A |
SEATTLE, WA, New biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today an expanded Series A.
>> Click here for more funding data on Juno Therapeutics
>> To export Juno Therapeuti... |
| 14.01.2014 | Amazon CEO adds second healthcare investment with cancer immunotherapy funding | Amazon founder Jeff Bezos has taken an interest in cancer immunotherapies. The investment in life science innovation marks a shift in his personal investment focus from the technology startups that he has favored. His investment in Juno The... |
| 23.12.2013 | Deals of the Year: The top 28 venture capital investments we tracked in 2013 | Venture capital investing in Washington state started out with a whimper in 2013, but it is ending with a bang.
After the slow start, as evidenced by the chart above from CB Insights in which just $100 million was invested in the first quar... |
| 05.12.2013 | Juno Therapeutics Raises $120M in Series A Funding | Juno Therapeutics Inc., a Seattle, WA-based clinical stage company that develops cancer immunotherapy products, has been founded with a $120m Series A funding.
Initial backers include ARCH Venture Partners and the Alaska Permanent Fund, thr... |
| 03.12.2013 | Cancer research startup Juno Therapeutics raises $120M in massive series A financing | In one of the largest series A venture capital deals this year in the biotechnology sector, Seattle-based Juno Therapeutics has landed $120 million in startup financing in a deal led by Arch Venture Partners and the Alaska Permanent Fund.
T... |
| - | Is too much money being invested in oncology? | Between venture capitalists flush with cash and corporate mergers and acquisitions, money is gushing into oncology.
The $1 billion-plus invested in Grail is the grand example, but every week, another big deal is announced. After spending $1... |
| - | Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss | Bristol Myers Squibb reported first-quarter revenue that topped expectations as sales of its popular blood cancer treatment Revlimid and blockbuster blood thinner Eliquis came in higher than expected.
The pharmaceutical giant posted a quart... |
| - | Bluebird bio announces positive CAR-T results | The CAR-T field can rest a little easier, reassured by Wednesday’s positive interim results from bluebird bio’s Phase 1 dose escalation study for an anti-BMCA CAR-T in relapsed/refractory multiple myeloma.
The news comes just one week after... |
| - | These infographics outline Editas’ post-IPO strategy | Cambridge gene editing startup Editas Medicine just filed for a $100 million IPO, marking it the first company that uses CRISPR technology to go public.
The company’s rise has been rapid: It was launched in 2013 with a $43 million Series A ... |
| - | Amazon CEO adds second healthcare investment with cancer immunotherapy funding | Amazon founder Jeff Bezos has taken an interest in cancer immunotherapies. The investment in life science innovation marks a shift in his personal investment focus from the technology startups that he has favored. His investment in Juno The... |
| - | Билл Гейтс вложился в редактирование ДНК | Богатейший человек в мире Билл Гейтс инвестировал в компанию Editas Medicine, занимающуюся разработкой нашумевшей технологии редактирования генома CRISPR/Cas9.
В состоявшемся раунде инвестиций Editas Medicine привлекла в целом $120 млн. Лид... |
| - | Sovereign wealth fund investment in healthcare is on the rise, especially in digital health | In the past couple of years there has been a rise in sovereign wealth funds’ investments in healthcare. These cover a wide range of areas from hospital chains to pharmaceutical companies, but it also includes direct investments in digital h... |
| - | New Series B brings cancer immunotherapy startup Juno Therapeutics to $310 million just this year | The burgeoning cancer immunotherapy space has tons of investors, to be sure, but perhaps no other startup has ever been as well-capitalized as Seattle-based Juno Therapeutics.
The company now has raised $310 million in the past year, having... |
| - | CRISPR gene editing: A commercial timeline | In just three years, CRISPR gene editing has hurtled to the forefront of biological science – with vast potential in agribusiness, human health, and industrial biotechnology. And unlike many nascent biotechs, which take years to attract sig... |
